Xylazine (‘Tranq’): What It Is, and Why It Changes How Overdoses Have to Be Handled

This is a public-health awareness piece, not medical advice. It draws on CDC surveillance data and clinical harm-reduction research to explain a real, documented shift in the illegal drug supply. The Never Use Alone hotline (800-484-3731) is a real, free service staffed to respond if something goes wrong.

There’s a specific, documented reason the last few years of the overdose crisis have gotten harder to respond to, even as opioid deaths overall have started to decline: a large share of the fentanyl supply is now mixed with something naloxone doesn’t touch. It’s called xylazine, street name “tranq,” and it’s changed both the physical toll of the drug supply and the actual, practical steps that can save someone’s life during an overdose.

What xylazine actually is

Xylazine is a veterinary sedative — not approved for human use at all — that’s increasingly being mixed into the illegal fentanyl supply, generally without the knowledge of the person using it. CDC surveillance data through its State Unintentional Drug Overdose Reporting System found xylazine present in 10.9% of fentanyl-involved overdose deaths across the 21 reporting jurisdictions by 2022, and its prevalence in overdose deaths increased 5.5-fold between 2019 and 2021 — a genuinely fast expansion into the drug supply in a very short window.

The critical fact that changes how overdoses have to be handled

This is the single most important, practical thing to know: xylazine is a sedative, not an opioid, which means naloxone — the medication that reliably reverses opioid overdoses — does not reverse xylazine’s effects. When fentanyl is mixed with xylazine, naloxone can still reverse the opioid component of an overdose, but a person may remain heavily sedated or unresponsive afterward specifically because of the xylazine still in their system. The real clinical guidance for 2026 reflects this directly: responders are now trained to still administer naloxone immediately in any suspected opioid overdose — it’s never harmful and can still save a life by reversing the fentanyl — but to also call emergency medical services and not assume a person is safe just because breathing has restarted, since xylazine’s sedative effects can persist independently.

The wound risk most people don’t know about

Xylazine carries a second, distinct health risk that has nothing to do with overdose: repeated exposure, particularly through injection, is associated with severe skin lesions, ulcerations, and abscesses — wounds that clinical research links specifically to xylazine exposure rather than to the opioids it’s mixed with. People with documented xylazine exposure are significantly more likely to develop an abscess serious enough to require medical attention. These wounds can appear even at injection sites unrelated to where the drug entered the body, which is part of what makes xylazine’s physical toll distinct from typical injection-related complications.

What actually reduces the risk

Xylazine test strips exist and have shown high accuracy at detecting xylazine in a drug sample, and using them alongside fentanyl test strips gives a much more complete picture of what’s actually in a given supply before it’s used. For anyone injecting drugs, the wound-specific harm-reduction guidance from clinical researchers is direct: use sterile injection equipment every time, rotate injection sites rather than reusing the same one repeatedly, allow skin and veins real time to heal between uses, and where possible, use methods other than injection to reduce the wound risk specifically tied to xylazine exposure.

The bottom line

The most important shift to understand isn’t abstract — it’s that the tools people have relied on for opioid overdose response, primarily naloxone, remain necessary but are no longer sufficient on their own in a supply that increasingly contains xylazine. Still give naloxone immediately in a suspected overdose — it’s never the wrong call — but call for emergency help every time and don’t treat restored breathing as confirmation that the danger has passed. That single piece of updated knowledge, more than any other change in the drug supply over the past several years, is what actually changes outcomes.